Hikma, GB00B0LCW083

Hikma stock after-hours at EUR 18.80: plus 0.80 percent versus prior close

Published on 10/02/2026 at 22:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hikma was at EUR 18.80 after-hours at 10:33 p.m. CEST on October 2, 2026, up 0.80 percent versus the Lang & Schwarz prior close. The company has named a CFO designate.

Fotorealistische sterile Pharma-Produktionslinie mit Injektionsfläschchen und Edelstahlanlagen
Hikma Pharmaceuticals PLC GB00B128J450 zeigt moderne Injektions-Produktionslinie in sterilem Pharmawerk mit Edelstahlanlagen, Illustration mit AI erstellt.

Hikma was at EUR 18.80 after-hours at 10:33 p.m. CEST on October 2, 2026, up 0.80 percent versus the prior close of EUR 18.65 at Lang & Schwarz.

Trading day and next update

Hikma’s next scheduled trading update is November 5, 2026, in line with its normal reporting timetable, according to an Hikma release. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Hikma stock.

Leadership and R&D plans

On September 24, 2026, Hikma Pharmaceuticals PLC announced the appointment of Rebecca Hall as chief financial officer and executive director. Hall is due to join in the first quarter of 2027, replacing Khalid Nabilsi, who will step down from the board on December 31, 2026, according to the company’s press release.

Hikma also said it aspires to spend around 5 percent to 6 percent of revenue on research and development going forward. Its announced R&D investor spotlight series begins on October 20, 2026, with sessions on solid orals and injectables scheduled for November 24 and December 16, respectively. The company said the seminars will be educational and will not provide new material financial or trading information, according to its release.

Disclaimer...

en | GB00B0LCW083 | HIKMA | boerse | 70218415 | bgmi